Depression and anxiety are usually discussed in terms of genetics, stressful life events, hormones, neurotransmitters, sleep, inflammation, and psychological factors. But a rapidly developing field of research is adding another biological system to the picture: the microorganisms living in the digestive tract.

Most attention has focused on gut bacteria. Yet bacteria are only part of the intestinal ecosystem. The human gut also contains fungi—the gut mycobiome—including species of Candida, Saccharomyces, Malassezia, and many others.

This raises an intriguing question: could an imbalance of intestinal fungi, particularly Candida albicans, influence mood, anxiety, or even depression?

The scientifically accurate answer is more interesting than either extreme.

There is now credible evidence that intestinal fungi can interact with the nervous, immune, endocrine, and metabolic systems involved in mental health. A human study has found increased Candida abundance in people experiencing a depressive episode, while animal experiments have shown that gastrointestinal colonization by Candida albicans can alter stress hormones and produce anxiety-like behavior. At the same time, current evidence does not establish intestinal Candida as a general cause of depression or anxiety in humans, and the simple presence of Candida in the gut is not evidence of disease. (pubmed.ncbi.nlm.nih.gov)

Understanding that distinction is essential.

Candida Is Not Automatically a Problem

Candida albicans is commonly described as an opportunistic fungus because it can exist harmlessly on mucosal surfaces but become pathogenic under certain conditions.

That does not mean that detecting Candida automatically indicates an infection or pathological “overgrowth.”

In a large study of 695 healthy adults, researchers detected intestinal C. albicans in 82.9% of participants using quantitative PCR. Its abundance varied considerably among individuals. In other words, Candida can be part of a normal intestinal ecosystem. (pubmed.ncbi.nlm.nih.gov)

The important biological question is therefore not simply:

“Is Candida present?”

It is:

“What is Candida doing within this particular microbial and immune ecosystem?”

A fungus may behave as a relatively quiet commensal under one set of conditions but interact very differently with the intestinal barrier, immune system, and neighboring microorganisms when the ecosystem becomes disturbed.

Researchers increasingly use the term pathobiont for organisms with precisely this dual character: normally tolerated members of the microbiota that have the potential to contribute to disease under particular environmental or host conditions. Reviews of the intestinal mycobiome emphasize that diet, medications, immunity, age, microbial competition, intestinal inflammation, and strain-level differences can all influence the behavior of Candida. (pubmed.ncbi.nlm.nih.gov)

The Missing Part of the Gut–Brain Axis: The Mycobiome

The microbiota–gut–brain axis is a network of bidirectional communication connecting the gastrointestinal tract and the central nervous system.

Signals can travel through several overlapping pathways, including the vagus nerve, immune mediators, microbial metabolites, stress hormones, intestinal barrier signaling, and the hypothalamic–pituitary–adrenal—or HPA—axis.

Much of the early research in this field treated “microbiome” almost as a synonym for bacteria. That is increasingly recognized as an incomplete picture.

Fungi represent only a small fraction of intestinal microorganisms by number, but biological importance does not necessarily correspond to abundance. Fungal cells are considerably larger than bacterial cells, contain highly immunologically active cell-wall molecules, and participate in complex interactions with both the host and neighboring bacteria.

A 2025 review dedicated specifically to the gut mycobiome and neuropsychiatric disorders concluded that emerging evidence connects altered fungal communities with depression, schizophrenia, bipolar disorder, autism spectrum disorders, and neurodegenerative disease. Proposed pathways include immune dysregulation, neuroinflammation, intestinal permeability, microbial interactions, and changes in metabolite signaling. (frontiersin.org)

The research is still young, but fungi can no longer be considered irrelevant to the gut–brain conversation.

What Do Human Studies Show About Candida and Depression?

One of the most directly relevant studies was published in Brain and Behavior in 2020.

Researchers analyzed stool samples from 24 people experiencing a current depressive episode and 16 healthy controls, examining both bacterial and fungal communities.

The depressive group showed an altered fungal ecosystem, reduced fungal alpha diversity, disrupted interactions between bacteria and fungi, and—most strikingly—higher relative abundance of the genus Candida. Penicillium abundance was lower.

A microbial signature combining four bacterial and four fungal genera distinguished patients from controls with an area under the ROC curve of approximately 0.84. (pubmed.ncbi.nlm.nih.gov)

That finding is provocative, but it is not proof that Candida caused depression.

The study was small and cross-sectional. Researchers examined people after depression was already present. Depression itself can change diet, sleep, medication use, physical activity, stress hormones, gastrointestinal motility, inflammation, and eating patterns—each of which could alter the microbiome.

This is one of the fundamental problems in microbiome psychiatry:

the gut can influence the brain, but the brain can also influence the gut.

Other depression studies show that the fungal story is more complicated

A much larger study published in 2023 examined 145 children and adolescents with depression and 110 matched controls. Their intestinal fungal composition differed significantly, and bacterial–fungal interaction networks were altered. However, the fungal taxa associated with depression were not identical to those found in the earlier adult study: Saccharomyces and Apiotrichum were enriched, while Aspergillus and Xeromyces were reduced. (pubmed.ncbi.nlm.nih.gov)

This inconsistency is scientifically important.

If Candida were a simple universal cause of depression, researchers would expect a much more reproducible Candida-dominant pattern across populations.

Instead, current evidence suggests something subtler: depression may be associated in some populations with disruption of the fungal ecosystem and of the interactions between fungi and bacteria, rather than with one universally abnormal fungus.

A 2025 metagenomic study added further support to the broader hypothesis. Researchers found significant differences in intestinal fungal communities between people with major depressive disorder and healthy controls. A fungal biomarker model performed well in two independent validation cohorts, achieving AUC values of approximately 0.884 and 0.838. The results are interesting as potential biomarkers, but they still demonstrate association rather than causation. (pubmed.ncbi.nlm.nih.gov)

The Most Compelling Candida–Anxiety Experiment

Human observational research can reveal associations, but animal models allow scientists to manipulate the gut ecosystem directly.

A particularly important experiment published in Psychoneuroendocrinology investigated whether gastrointestinal colonization by Candida albicans could affect the brain.

Researchers colonized adolescent female mice with C. albicans. The animals subsequently displayed increased anxiety-like behavior, increased basal corticosterone—the principal stress hormone in rodents—and abnormal corticosterone responses to acute stress.

The researchers also discovered alterations in lipid metabolism and in the endocannabinoid system, including changes involving anandamide signaling.

Importantly, this was gastrointestinal colonization rather than an experimentally induced fungal infection of the brain. (pmc.ncbi.nlm.nih.gov)

The experiment provides an important proof of principle:

a gut fungus can, under experimental conditions, alter neuroendocrine signaling and behavior without needing to invade the brain.

But mice are not humans, anxiety-like behavior in laboratory animals is not identical to an anxiety disorder, and experimental colonization cannot automatically be extrapolated to ordinary Candida carriage in people.

The study therefore supports biological plausibility—not a diagnosis.

How Could Candida in the Gut Influence the Brain?

There is unlikely to be one single Candida-to-brain pathway. If intestinal fungi contribute to psychiatric symptoms in some individuals, several interconnected mechanisms are more plausible.

1. Immune Activation and Inflammation

One of the strongest biological links involves the immune system.

The fungal cell wall contains molecules such as β-glucans and mannans that are detected by specialized pattern-recognition receptors of the immune system. One particularly well-studied receptor is Dectin-1, which recognizes fungal β-glucans.

Activation of fungal-recognition pathways can influence production of cytokines including TNF-α, IL-1β, IL-6, IL-17, and other immune mediators, depending on fungal morphology, tissue environment, and immune context.

Why does this matter for depression?

Because inflammation is increasingly recognized as biologically relevant to a subset of depressive disorders.

A systematic review and meta-analysis of inflammatory markers in clinically significant depression, anxiety, and PTSD found evidence of inflammatory alterations, particularly in depression. This does not mean that depression is simply an inflammatory disease, but it demonstrates that immune signaling and psychiatric symptoms can intersect. (pubmed.ncbi.nlm.nih.gov)

A plausible pathway could therefore look like this:

intestinal fungal imbalance → altered mucosal immune stimulation → systemic inflammatory signaling → changes in neural and neuroendocrine function.

What has not been demonstrated is that Candida is usually the initiating factor in this chain in people with depression.

2. The Intestinal Barrier

The intestinal epithelium forms a selective barrier between the immense microbial ecosystem inside the gut and the body’s internal environment.

When that barrier is functioning normally, immune exposure to microbes is tightly controlled. When intestinal barrier integrity becomes impaired, microbial molecules can interact more strongly with mucosal and systemic immune pathways.

Candida albicans itself can exist peacefully in the intestinal lumen, but the relationship changes when the microbiome becomes severely disrupted, mucosal immunity is impaired, or the epithelial barrier is damaged. Under extreme clinical circumstances, intestinal Candida can even cross the epithelial barrier and contribute to systemic candidiasis—although this is fundamentally different from ordinary colonization in otherwise healthy people.

Meanwhile, research increasingly connects altered intestinal permeability with psychiatric disorders.

A 2025 systematic review and meta-analysis found that people with depressive symptoms had significantly higher levels of several markers associated with intestinal epithelial damage, permeability, or inflammatory responses to microbial products, including I-FABP, zonulin, antibodies against bacterial endotoxins, and soluble CD14. The authors also emphasized the substantial heterogeneity and the fact that causal relationships remain uncertain. (pmc.ncbi.nlm.nih.gov)

This provides another potential intersection between intestinal dysbiosis and mental health—but again, these findings are not Candida-specific.

For readers who want to explore this side of gut health further, supporting intestinal cleansing and a healthier gut environment may be a useful place to start.

3. Stress Hormones and the HPA Axis

The HPA axis regulates the physiological stress response.

Chronic abnormalities of this system have long been investigated in depression and anxiety. The gut microbiome can interact with the HPA axis, while psychological stress can simultaneously modify gut physiology.

The Candida mouse experiment is particularly interesting here because colonized animals displayed elevated basal corticosterone and abnormal hormonal responses to stress. (pubmed.ncbi.nlm.nih.gov)

But the relationship is likely bidirectional.

Chronic stress can alter intestinal motility, secretion, immune activity, eating behavior, microbial composition, and barrier function. Therefore, a person experiencing chronic anxiety could theoretically develop changes in gut microbial ecology, including changes in fungi.

This creates a possible feedback loop:

stress affects the gut, the altered gut affects immune and metabolic signals, and those signals may influence stress responsiveness.

Trying to identify a single starting point may therefore be misleading.

4. The Endocannabinoid System

The endocannabinoid system is best known for its involvement in cannabinoid signaling, but its physiological functions extend much further.

Endocannabinoids regulate stress adaptation, appetite, pain, inflammation, emotional processing, memory, and synaptic signaling.

The C. albicans mouse study found altered levels of endocannabinoids and related lipids in both the gastrointestinal tract and brain. Researchers specifically identified dysregulation involving anandamide (AEA), a signaling molecule known to participate in anxiety regulation.

Even more intriguingly, experimentally altering the pathway reversed aspects of the anxiety-related phenotype in the animals. (pmc.ncbi.nlm.nih.gov)

This does not establish a Candida–endocannabinoid disorder in humans, but it provides a sophisticated biological mechanism that extends well beyond the simplistic idea that fungi must physically enter the brain to affect behavior.

5. Candida May Matter Through Its Bacterial Neighbors

Another major mistake is to consider Candida in isolation.

The gut is an ecosystem.

Bacteria can inhibit or promote fungi. Fungi can change bacterial community structure. Both compete for nutrients, modify the local environment, exchange metabolites, and influence immune responses.

Short-chain fatty acids such as butyrate, propionate, and acetate, largely produced through bacterial fermentation, are particularly important.

A 2024 review in Trends in Microbiology summarized evidence that bacterial short-chain fatty acids can restrain C. albicans growth, inhibit invasive fungal behavior, alter fungal gene expression, and change fungal antigens recognized by the immune system. (pubmed.ncbi.nlm.nih.gov)

This means that an increase in Candida might sometimes be a consequence of losing bacterial ecological control rather than the primary problem itself.

This is also why approaches centered on fiber, regular intestinal transit, and supporting the gut’s natural cleansing processes may make more biological sense than simply trying to eliminate one microorganism.

Broad-spectrum antibiotics provide a clear example: they can remove bacteria that normally contribute to colonization resistance, creating an ecological opportunity for Candida expansion.

This concept may help explain why research on depression frequently finds disturbances involving entire bacterial–fungal networks, rather than one isolated microorganism.

6. Tryptophan, Kynurenine, and Neuroactive Metabolism

Another proposed pathway connects immune activation with amino-acid metabolism.

Tryptophan can be used to support serotonin synthesis, but it can also be metabolized through the kynurenine pathway. Inflammatory immune signaling can influence enzymes controlling this pathway and therefore alter the balance of neuroactive metabolites.

Experimental immune activation and clinical studies have linked kynurenine-pathway changes with depressive symptoms, although the human literature remains complex and heterogeneous. (pmc.ncbi.nlm.nih.gov)

It is biologically conceivable that chronic microbial immune stimulation could contribute to such metabolic changes.

However, there is currently insufficient evidence to say:

Candida increases kynurenine metabolism, which causes depression in humans.

That statement goes several steps beyond the available research.

A more accurate interpretation is that fungal-driven inflammation represents one possible upstream influence among many that could interact with pathways already implicated in depression.

Candida, Depression, and Anxiety: Association Is Not Causation

This distinction is the central scientific issue.

When researchers find more Candida in people with depression, several explanations are possible.

Candida could contribute to physiological processes that increase vulnerability to depressive symptoms. Depression could change diet, immunity, medications, sleep, stress hormones, or gut function in ways that favor Candida. A third factor—such as antibiotics, inflammatory disease, metabolic dysfunction, diet, or chronic stress—could independently increase both fungal dysbiosis and depression risk. Or Candida could simply be one marker of a larger ecological disturbance involving bacteria, fungi, metabolites, and host immunity.

These explanations are not mutually exclusive.

Longitudinal studies, mechanistic human research, and carefully controlled intervention trials will be required to distinguish them.

What About Candida in Other Psychiatric Disorders?

Some intriguing evidence extends beyond depression and anxiety.

Researchers studying schizophrenia and bipolar disorder have reported associations between immune responses to Candida albicans and specific psychiatric or cognitive outcomes.

In a study involving hundreds of participants, Candida IgG seropositivity showed sex-specific associations with schizophrenia and with cognitive performance. Among women with schizophrenia or bipolar disorder, Candida seropositivity was associated with poorer performance in particular memory domains. (pubmed.ncbi.nlm.nih.gov)

Another study following people with chronic schizophrenia found that individuals with a Candida-dominated intestinal fungal enterotype had more severe positive symptoms and depression-related factors than those with a Saccharomyces-dominated profile. Candida abundance correlated positively with depression factors in that cohort.

These findings strengthen the case for investigating fungi in psychiatric research.

They do not establish fungal infection as the cause of these disorders.

Does a Positive Candida Test Explain Depression or Anxiety?

Usually, no.

Because Candida commonly colonizes healthy people, detecting it in a stool sample does not by itself demonstrate disease.

The gut mycobiome is also technically difficult to measure. Fungal abundance varies substantially among people and can be influenced by recent diet, medications, geography, laboratory methodology, DNA extraction techniques, sequencing primers, and even whether detected fungal material originated from persistent colonization or food-associated organisms passing temporarily through the intestine.

Clinical reviews therefore emphasize that the field still lacks a universally accepted definition of a “normal” intestinal mycobiome. (pubmed.ncbi.nlm.nih.gov)

For the same reason, an elevated Candida antibody level does not automatically establish pathological intestinal overgrowth or prove that psychiatric symptoms are fungal in origin.

There is currently no validated clinical test that can diagnose depression or anxiety as a Candida-driven disorder.

Will Antifungal Treatment Improve Depression or Anxiety?

This is where scientific caution becomes especially important.

Despite the biological mechanisms and associations discussed above, there are currently no high-quality clinical trials demonstrating that treating intestinal Candida with antifungal drugs is an effective treatment for ordinary major depressive disorder or anxiety disorders.

A small randomized placebo-controlled pilot study in people with schizophrenia found that probiotic treatment reduced C. albicans antibody levels in men and appeared to improve some gastrointestinal measures. The psychiatric findings were exploratory and were not sufficient to establish a Candida-targeted psychiatric treatment. (pubmed.ncbi.nlm.nih.gov)

This is important because biological plausibility is not the same as therapeutic evidence.

Antifungal medicines can cause adverse effects, interact with other medications, alter microbial ecology, and contribute to antifungal resistance. They are valuable medicines when used for appropriately diagnosed fungal disease—not experimental mood supplements.

Likewise, extreme “Candida cleanse” diets should not substitute for evidence-based treatment of depression or anxiety.

A More Useful Way to Think About the Evidence

Rather than asking whether Candida “causes depression,” it may be more scientifically productive to think in terms of biological susceptibility networks.

A person may simultaneously have chronic stress, disturbed sleep, poor dietary diversity, altered bacterial fermentation, reduced short-chain fatty-acid production, intestinal inflammation, changes in fungal ecology, increased immune signaling, and altered neuroendocrine responses.

Within such a network, Candida could potentially act as one amplifier among several interacting factors.

For another individual, it may be almost completely irrelevant.

This model is consistent with the growing recognition that both major depression and anxiety disorders are biologically heterogeneous conditions. The same diagnostic label can arise from different combinations of genetic vulnerability, life experience, neurobiology, immune status, metabolic health, and environmental exposures.

The microbiome—including the mycobiome—may eventually help researchers identify biologically distinct subgroups of patients rather than provide one universal microbial explanation for mental illness.

What Can You Do Now?

The practical implications of this research are less dramatic than many online Candida claims—but considerably more useful.

Persistent depression or anxiety deserves proper clinical evaluation and evidence-based treatment. Gastrointestinal symptoms should also be investigated on their own merits rather than automatically attributed to Candida. If genuine candidiasis is suspected, diagnosis should be based on the clinical context and appropriate medical testing.

At the same time, supporting overall gut health is reasonable because many factors that benefit the intestinal ecosystem also support broader metabolic and neurological health.

A useful next step is to understand how intestinal cleansing, regularity, and gut-barrier health fit into the bigger picture rather than focusing exclusively on Candida.

Dietary diversity, adequate intake of fiber-rich plant foods, regular physical activity, sufficient sleep, appropriate stress management, and avoiding unnecessary antibiotics can all help preserve microbial resilience.

For people looking for a practical way to increase their focus on plant-derived fiber and digestive regularity, a comprehensive fiber-based gut support formula can also fit into this broader lifestyle approach.

These measures are not “Candida cures,” and they should not be presented as substitutes for psychiatric care.

The important idea is ecological rather than antifungal:

a resilient gut ecosystem usually depends on maintaining healthy relationships among microbes rather than attempting to eliminate every organism capable of becoming pathogenic.

So, Can Candida in the Gut Cause Depression and Anxiety?

The most accurate answer today is:

Potentially, intestinal fungi can influence biological pathways involved in mood and anxiety—but we do not yet know how often this contributes meaningfully to psychiatric disease in humans.

There is credible evidence that:

Candida albicans can directly alter gut–brain signaling and anxiety-like behavior in experimental animals.

People experiencing depression can have altered intestinal fungal communities, and some studies have found increased Candida abundance.

Fungi can influence immune activation, intestinal barrier signaling, bacterial communities, stress physiology, and neuroactive metabolic pathways.

But there is not yet convincing evidence that:

ordinary intestinal Candida colonization is a common direct cause of depression or anxiety;

a positive stool Candida result identifies the cause of psychiatric symptoms;

or antifungal treatment is an established therapy for depression or anxiety.

That distinction matters.

The emerging science of the mycobiome–gut–brain axis is challenging the old idea that gut fungi are passive passengers. They appear capable of communicating with immunity, metabolism, and the nervous system in ways researchers are only beginning to understand.

But the most important discovery may ultimately be broader than Candida itself.

Mental health is influenced not simply by the brain in isolation, nor by a single microorganism, but by a highly interconnected biological system in which the brain, gut, immune system, endocrine system, diet, lifestyle, bacteria, and fungi continuously influence one another.

Understanding those interactions may eventually allow psychiatry to move beyond asking whether one microbe “causes” depression—and toward identifying which biological pathways are disturbed in which individual patient.

---

Bibliography

1. Hadrich I, Turki M, Chaari I, et al. Gut mycobiome and neuropsychiatric disorders: insights and therapeutic potential. Frontiers in Cellular Neuroscience. 2025;18:1495224. Scientific article / PubMed

2. Musumeci S, Coen M, Leidi A, Schrenzel J. The human gut mycobiome and the specific role of Candida albicans: where do we stand, as clinicians? Clinical Microbiology and Infection. 2022;28(1):58–63. Scientific article / PubMed

3. Delavy M, Sertour N, Patin E, et al. Unveiling Candida albicans intestinal carriage in healthy volunteers: the role of micro- and mycobiota, diet, host genetics and immune response. Gut Microbes. 2023;15(2):2287618. Scientific article / PubMed

4. Kreulen IAM, de Jonge WJ, van den Wijngaard RM, van Thiel IAM. Candida spp. in Human Intestinal Health and Disease: More than a Gut Feeling. Mycopathologia. 2023. Scientific article / PubMed

5. Jiang HY, Pan LY, Zhang X, Zhang Z, Zhou YY, Ruan B. Altered gut bacterial-fungal interkingdom networks in patients with current depressive episode. Brain and Behavior. 2020;10(8):e01677. Scientific article / PubMed

6. Hao SR, et al. Altered gut bacterial-fungal interkingdom networks in children and adolescents with depression. Journal of Affective Disorders. 2023. Scientific article / PubMed

7. Wang X, Cao D, Chen W, Sun J, Hu H. Metagenomics reveals unique gut mycobiome biomarkers in major depressive disorder – a non-invasive method. Frontiers in Cellular and Infection Microbiology. 2025;15:1582522. Scientific article / PubMed

8. Markey L, Hooper A, Melon LC, et al. Colonization with the commensal fungus Candida albicans perturbs the gut-brain axis through dysregulation of endocannabinoid signaling. Psychoneuroendocrinology. 2020;121:104808. Scientific article / PubMed

9. McCrory C, Lenardon M, Traven A. Bacteria-derived short-chain fatty acids as potential regulators of fungal commensalism and pathogenesis. Trends in Microbiology. 2024;32(11):1106–1118. Scientific article / PubMed

10. Zeise KD, Woods RJ, Huffnagle GB. Interplay between Candida albicans and Lactic Acid Bacteria in the Gastrointestinal Tract: Impact on Colonization Resistance, Microbial Carriage, Opportunistic Infection, and Host Immunity. Clinical Microbiology Reviews. 2021;34(4):e00323-20. Scientific article / PubMed

11. Peirce JM, Alviña K. The role of inflammation and the gut microbiome in depression and anxiety. Journal of Neuroscience Research. 2019;97(10):1223–1241. Scientific article / PubMed

12. Kuring JK, Mathias JL, Ward L, Tachas G. Inflammatory markers in persons with clinically-significant depression, anxiety or PTSD: A systematic review and meta-analysis. Journal of Psychiatric Research. 2023;168:279–292. Scientific article / PubMed

13. Wasiak J, Gawlik-Kotelnicka O. Intestinal permeability and its significance in psychiatric disorders – A narrative review and future perspectives. Behavioural Brain Research. 2023;448:114459. Scientific article / PubMed

14. Morena D, Lippi M, Scopetti M, Turillazzi E, Fineschi V. Leaky Gut Biomarkers as Predictors of Depression and Suicidal Risk: A Systematic Review and Meta-Analysis. Diagnostics. 2025;15(13):1683. Scientific article / PubMed

15. The gut microbiota in anxiety and depression – A systematic review. Clinical Psychology Review. 2021;83:101943. Scientific article / PubMed

16. Severance EG, Gressitt KL, Stallings CR, et al. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. npj Schizophrenia. 2016;2:16018. Scientific article / PubMed

17. Severance EG, Gressitt KL, Stallings CR, et al. Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study. Brain, Behavior, and Immunity. 2017;62:41–45. Scientific article / PubMed

18. Effect of Immune Activation on the Kynurenine Pathway and Depression Symptoms – A Systematic Review and Meta-Analysis. Full scientific article / PubMed Central